title: BCL2 genotypes and prostate cancer survival.
abstract: OBJECTIVE
  The antiapoptotic B‑cell lymphoma 2 (BCL2) gene is a key player in cancer development and progression. A functional single-nucleotide polymorphism (c.-938C>A, rs2279115) in the inhibitory P2 BCL2 gene promoter has been associated with clinical outcomes in various types of cancer. Aim of the present study was to analyze the role of BCL2-938C>A genotypes in prostate cancer mortality.
  
  
  METHODS
  The association between BCL2-938C>A (rs2279115) genotypes and prostate cancer outcome was studied within the prospective PROCAGENE study comprising 702 prostate cancer patients.
  
  
  RESULTS
  During a median follow-up time of 92 months, 120 (17.1%) patients died. A univariate Cox regression model showed a significant association of the CC genotype with reduced cancer-specific survival (CSS; hazard ratio, HR, 2.13, 95% confidence interval, CI, 1.10-4.12; p = 0.024) and overall survival (OS; HR 2.34, 95% CI 1.58-3.47; p < 0.001). In a multivariate Cox regression model including age at diagnosis, risk group, and androgen deprivation therapy, the CC genotype remained a significant predictor of poor CSS (HR 2.05, 95% CI 1.05-3.99; p = 0.034) and OS (HR 2.25, 95% CI 1.51-3.36; p < 0.001).
  
  
  CONCLUSIONS
  This study provides evidence that the homozygous BCL2-938 CC genotype is associated with OS and C in prostate cancer patients.
authors.affiliation: Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036, Graz, Austria. wilfried.renner@medunigraz.at.
authors.forename: Wilfried
authors.identifier: http://orcid.org/0000-0002-6199-4382
authors.initials: W
authors.lastname: Renner
authors.affiliation: Division of Internal Medicine, GKK Outpatient Department, Graz, Austria.
authors.forename: Uwe
authors.initials: U
authors.lastname: Langsenlehner
authors.affiliation: Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
authors.forename: Sabine
authors.initials: S
authors.lastname: Krenn-Pilko
authors.affiliation: Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Eder
authors.affiliation: Department of Therapeutic Radiology and Oncology, Medical University of Graz, Graz, Austria.
authors.forename: Tanja
authors.initials: T
authors.lastname: Langsenlehner
mesh_terms: D000368:Aged; D000483:Alleles; D000726:Androgen Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005838:Genotype; D006720:Homozygote; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal; D016019:Survival Analysis
chemical_list: D000726:Androgen Antagonists; C000595707:BCL2 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2
keywords: Apoptosis; Genetics; Oncogene; Polymorphism; Radiotherapy